美国老年人四种可预防疾病疫苗接种的成本效益分析
该研究用基于人群的年龄结构经济模型,对美国50岁及以上成人接种流感、百日咳、带状疱疹和肺炎球菌疫苗进行30年成本效益分析。
要点
- 当前老年人疫苗接种相较不接种,30年社会视角效益成本比为1.4。
- 提高接种覆盖率相较当前覆盖率,30年社会视角效益成本比为1.2。
- 结果对疾病发病率、疫苗效力和接种所需时间 productivity 成本最敏感。
核心结论
- 美国老年人疫苗接种项目具有经济价值,进一步提高接种覆盖率可能是有必要且经济上合理的。
研究设计与样本
- 基于人群的年龄结构经济模型,对50岁及以上美国成人四种疾病疫苗接种进行成本效益分析,考虑人口老龄化,每种疾病使用独立决策树,预测30年内贴现的接种人数、病例数和直接医疗与间接成本(2018年美元)。
关键数值与推荐
- 确定性敏感性分析显示结果对疾病发病率、疫苗效力和接种所需时间 productivity 成本最敏感。
临床怎么用
- 研究结果支持维持并提升美国老年人流感、百日咳、带状疱疹和肺炎球菌疫苗接种覆盖率,作为具有经济价值的人群预防策略。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This exploratory study estimates the economic value of the current vaccination program and increased coverage against four preventable diseases in older adults in the United States (US). METHODS: A population-based, age-structured economic model was used to conduct a cost-benefit analysis of vaccination against influenza, pertussis, herpes zoster, and pneumococcal disease among US adults aged 50 years and older, accounting for aging of the population. The model used separate decision trees for each disease to project the discounted number of vaccinated individuals, number of disease cases, and direct medical and indirect costs (2018 US$) over a 30-year period. Benefit-cost ratios (BCRs) and net present values were calculated for two primary analyses comparing current vaccination coverage versus no vaccination and comparing increased coverage versus current coverage. Key parameter values were varied in deterministic sensitivity analyses. RESULTS: Current adult vaccination coverage (vs. no vaccination) is estimated to result in nearly 65 million averted disease cases, $185 billion averted costs of cases, and $136 billion in incremental vaccination costs over a 30-year period from a societal perspective (BCR = 1.4). Increased vaccination coverage (vs. current coverage) is associated with over 33 million additional averted disease cases, $96 billion additional averted costs of cases, and nearly $83 billion in incremental vaccination costs, resulting in a societal BCR of 1.2 over 30 years. Deterministic sensitivity analyses demonstrated that results were most sensitive to disease incidence, vaccine efficacy, and productivity costs for time required for vaccination. CONCLUSIONS: Study results highlight the economic value of vaccination programs for older adults in the US and indicate that efforts to further increase vaccination coverage may be warranted and economically justifiable.
引用
- Carrico J, Talbird SE, La EM, et al. Cost-benefit analysis of vaccination against four preventable diseases in older adults: Impact of an aging population. Vaccine. 2021. PMID: 34334253. doi:10.1016/j.vaccine.2021.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。